News | Structural Heart | May 16, 2016

Older AFib Patients at Greater Risk of Post-Mitral Valve Repair Tricuspid Regurgitation

Study presented at American Association for Thoracic Surgery annual meeting identifies additional risk factors

AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation

May 16, 2016 — Tricuspid regurgitation (TR) occurs when the heart’s tricuspid valve leaks, allowing blood to flow back from the right ventricle to the right atrium. TR can be secondary to disorders of left-sided heart valves (mitral or aortic). At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a long-term study of patients who underwent mitral valve (MV) repair. They found that although newly developed TR after MV repair was rare, the risk could increase in older patients with atrial fibrillation and impaired heart function.

“Patients who develop TR after MV repair for degenerative diseases are older, have chronic atrial fibrillation, more advanced functional class and impaired left ventricular function at the time of the initial surgery. This is yet another compelling reason to correct mitral regurgitation early,” explained Tirone E. David, M.D., Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital and the University of Toronto.

The study included 1,171 patients who had undergone MV repair between 1985 and 2010, with periodic clinical and echocardiographic assessments for around nine years following surgery. Sixty percent of the patients were men and the average age was 58 years. Preoperatively, 44 percent were classified in New York Heart Association (NYHA) functional classes III and IV for heart failure. In addition to MV repair, 17.1 percent of patients also underwent coronary artery bypass, 11.2 percent had surgical ablation to treat atrial fibrillation (the maze procedure), and 4.7 percent had tricuspid annuloplasty to surgically repair the tricuspid valve using an annuloplasty ring.

Forty-five patients (3.3 percent) developed moderate or severe TR, fourteen of whom had undergone previous surgery to repair the tricuspid valve.

“Although the number of patients who developed TR after MV repair was small in our study, the effect of severe TR was devastating, with a high mortality at one year after the diagnosis, which usually occurred during an episode of heart failure,” commented David.

The investigators found that two factors were significantly predictive of developing TR: older age and preoperative atrial fibrillation. In fact, preoperative atrial fibrillation was associated with a three-fold increased risk of TR. Other factors that appear to be associated with postoperative moderate-to-severe TR are insertion of a permanent pacemaker and the grade of TR within the first month of MV surgery.

Enlarged size of the ring-shaped tissue surrounding the leaflets of the valve, known as the annulus, is thought to be a risk factor for the development of TR. European guidelines on the management of heart valve diseases recommend ≥40 mm as the size indication for tricuspid annuloplasty. However, in this study all patients who developed TR often had tricuspid annulus diameters less than 40 mm, as well as less than moderate TR by echocardiography at the time of the MV repair.

About 25 percent of cases of TR are caused by rheumatic disease, endocarditis, carcinoid disease, traumatic injury or pacemakers/defibrillators. More commonly, TR is caused by left heart disease resulting in pulmonary hypertension, chronic lung disease, pulmonary thromboembolism or right ventricular dysfunction. The diet drug Fen-Phen was also linked to TR.

Symptoms of TR may be difficult to detect but may include weakness and fatigue, active pulsing in the neck veins, reduced urinary output, and swelling in the legs, ankles, feet, or abdomen. Mortality may be attributed to the underlying conditions that cause TR rather than TR itself.

For more information: www.aats.org

Related Content

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...

An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.

Feature | Atrial Fibrillation | September 13, 2018
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time
Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 24, 2018
Atrial fibrillation patients who are diagnosed with carotid artery disease face higher risks for developing dementia,...
Overlay Init